Non-Invasive Prenatal Testing Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Non-Invasive Prenatal Testing Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The Non-Invasive Prenatal Testing Market is expected to grow at a CAGR of 14.4% during the forecast period (2022-2027).

Though the COVID-19 pandemic continues to transform the growth of the various markets, the immediate impact of the outbreak is varied. The outbreak is expected to show an impact on the non-invasive prenatal testing (NIPT) market due to the hold on non-invasive prenatal screening (NIPS) services to prevent the spread of the COVID-19 virus. The tremendous pressure on the hospitals to provide services to COVID-19 patients is also one of the factors inhibiting the hospitals and diagnostic centers from providing non-invasive prenatal screening (NIPS) services. As per the study "Implementation of the Publicly Funded Prenatal Screening Programme in Poland during the COVID-19 Pandemic: A Cross-Sectional Study" published in the Journal of "Clinical Medicine" in March 2022, in Poland, the number of patients enrolled in the prenatal testing program fell in 2020 compared to the previous year. In Poland, the number of integrated screening tests declined along with the number of newborns, while the percentage of triple tests increased. The number of invasive diagnostic tests was also reduced significantly. Therefore, it is expected to have a negative impact on the target market during the forecast period.

The factors propelling the growth of the market are increasing number of babies with chromosomal disorders owing to increasing number of late pregnancies, increasing demand for early and non-invasive fetal diagnosis, and favorable reimbursement policies. The increasing number of stillbirth cases across the world is also expected to offer a sizeable growth opportunity for early disease diagnosis. According to the Australian Institute of Health and Welfare, data updated in December 2020, the rate of stillbirth in Australia is 6.7 per 1,000 births, which equals almost 2,200 families each year. One in every 137 women who reach the 20-weeks-gestation may have a stillborn child. Hence, with the increasing cases of stillbirths, the demand for testing increases, in turn, it is expected to aid the overall market growth during the forecast period.

Additionally, advantages of non-invasive prenatal tests over other prenatal tests, such as their non-invasive nature, better accuracy, and short duration of the procedure, are anticipated to hasten the growth of the global NIPT market during the forecast period. However, the lack of accessibility of the test in emerging countries, ethical concerns, and strict government regulations are the few factors that will hamper the growth of the global NIPT market. For instance, in April 2022, United States Food and Drug Administration is alerting the public about the risk of misleading results, improper use, and inappropriate interpretation of results (NIPT).

Down syndrome is a chromosomal disorder, also called trisomy 21, trisomy G, 47, XX,+21, and 47, XY,+21. It includes certain birth defects, learning problems, and deformities of facial features. A child with Down syndrome may also have heart defects and problems with vision and hearing. According to the Centers for Disease Control and Prevention, data updated in April 2021, down syndrome is the most common chromosomal condition diagnosed in United States. Every year, about 6,000 babies born in United States have Down syndrome. This means that Down syndrome occurs in about 1 out of every 700 babies. Hence, the growing incidence rate of down syndrome is expected to create lucrative opportunities for the target industry growth during the forecast period.

Non-invasive prenatal testing (NIPT) consists of analyzing cell-free DNA (cfDNA) circulating in the mother’s blood to detect Down syndrome.​ With the successful introduction of NIPT, for the detection of Down syndrome, into routine prenatal care, it is important to understand the risks, benefits, and limitations to guide patients in making an informed decision. Non-invasive prenatal testing (NIPT) offers several clinical benefits over existing prenatal screening tests, such as maternal serum screening (MSS). According to the study by Stanislav Birko et.al published in January 2022, for the screening of Down syndrome, non-invasive prenatal testing (NIPT) can be performed as early as the ninth week of pregnancy, holds no risk of miscarriage, and can detect the presence of Down syndrome (trisomy 21) with high sensitivity (99.9%) and specificity (98%). As a result, the demand for these technologies has increased and is being adopted by many developing countries, which is expected to drive the segment’s growth.

North America is expected to hold a leading position in the Non-invasive prenatal testing (NIPT) market during the forecast period. High preterm birth rate, high maternal mortality rate, and rising incidences of chromosomal abnormalities will likely increase the adoption and demand for tests in this region. as per the research article by Cereda A and Carey JC on "The Trisomy 18 Syndrome" published in May 2020, Edwards Syndrome affects one out of every 4,000 babies born. However, because it may go unnoticed, the incidence during pregnancy is substantially higher. Many women experience miscarriages and stillbirths when their fetus has trisomy 18. Thus, North America is expected to dominate the Non-invasive prenatal testing (NIPT) market over the forecast period on the account of growing burden of chromosomal abnormalities among fetuses.

Furthermore, high rates of diagnosis, wider adoption and awareness among the people, and the introduction of new and technologically advanced tests are also contributing to the growth of the market in North America. For instance, in May 2021, Yourgene launched IONA Care, a non-invasive prenatal test (NIPT) service offering along with an extended clinical menu measuring the likelihood that a pregnant woman is carrying a fetus with sex chromosome aneuploidies (SCA) and autosomal aneuploidies (AA), in addition to the current IONA test which offers screening for trisomies 21, 18 and 13 and fetal sex determination. Hence, Such a factor will have a positive influence on the target market growth in the forecasted period.

The non-invasive prenatal testing market is very competitive with most of the players competing to maximize their market shares. Strong competition, rapid technological advancements, recurrent changes in government policies, and prices are key factors that confront the market. Key market players in the market are BGI, Eurofins Scientific, F. Hoffmann-La Roche Ltd, Invitae Corporation, Illumina, Inc., Natera, Inc., Qiagen, Laboratory Corp. of America Holdings, Quest Diagnostics, among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support